— Ipsen commits to creating global hub in North America, expects to add more than 200 jobs —
BOSTON, June 7, 2018 – Today, Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical
group, announced it will establish its North American headquarters in Cambridge, Massachusetts.
The announcement was made at the 2018 BIO International Convention in Boston with the Massachusetts Life Sciences Center (MLSC), an economic development investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts.
Ipsen will create its third global headquarters by consolidating its U.S. business in Cambridge, the
leading global biotech hub. Ipsen will co-locate its North America business with its Global External
Innovation and Partnering, R&D and Manufacturing teams, as well as certain global Commercial
roles, creating a fully integrated biopharmaceutical business in the US.
“We are entering into a new era of innovation and growth for Ipsen as a leading global biotech
company. By bringing our headquarters to Cambridge, we will build a sustainable innovation
engine to advance opportunities for our employees and our overall business,” said Richard
Paulson, CEO of Ipsen North America. “The MLSC has been instrumental throughout this
process, and we look forward to continuing to partner with them as we grow our footprint even
further in Cambridge and ultimately address patient needs.”
Ipsen will capitalize on Cambridge’s biotech ecosystem to support its accelerated growth, raise its
profile and visibility as an employer and partner of choice. Ipsen already has an established
presence in Cambridge with two sites in Kendall Square: a manufacturing site located in One
Kendall Square and the 650 East Kendall Street offices, which houses its Global External
Innovation and Partnering, and Research & Development activities.
“Our administration is committed to supporting strategic investments in life sciences, research
and development and is pleased that Ipsen has chosen to expand its footprint by relocating its
headquarters to here in the Commonwealth,” said Massachusetts Governor Charlie Baker.
“Massachusetts continues to be a global leader in the life sciences industry and we welcome
Ipsen’s planned growth in employment and investment that will spur continued innovation,
collaboration and economic growth.”
Ipsen’s U.S. headquarters, currently based in Basking Ridge, NJ, will transition to Cambridge
over the next 12 months. Ipsen’s two additional global biotech hubs will remain in the United
Kingdom and France. The organization will also maintain a core services center in Basking Ridge,
NJ. For more information on partnering with Ipsen, please visit: https://www.ipsen.com/partners/.
About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is a U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global
specialty-driven biopharmaceutical group focused on innovation and specialty care. The U.S.
head office is currently located in Basking Ridge, New Jersey, and its Canadian office, Ipsen
Biopharmaceuticals Canada, Inc., an integrated business unit within North America, is located in
Mississauga, Ontario. Additional research and development and manufacturing sites are located
in Cambridge, Massachusetts, as part of Ipsen Bioscience, Inc., the Ipsen U.S. research and
development center, which is focused on the discovery of potentially highly differentiated and
competitive products in Oncology, Neuroscience and Rare Diseases. Ipsen North America
employs approximately 600 people and is dedicated to providing hope for the patients whose
lives are challenged by difficult-to-treat diseases. At Ipsen, we focus our resources, investments
and energy on discovering, developing and commercializing new therapeutic options for
oncologic, neurologic and rare diseases. For more information on Ipsen in North America, please
visit www.ipsenus.com or www.ipsen.ca.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty
care. The group develops and commercializes innovative medicines in three key therapeutic
areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified
through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal
cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare
business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115
countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused
on its innovative and differentiated technological platforms located in the heart of the leading
biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The
Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the
United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
For more information on Ipsen, visit www.ipsen.com.
More about the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an economic development investment
agency dedicated to supporting the growth and development of the life sciences in
Massachusetts, home to the most verdant and productive life sciences ecosystem in the world.
Through public-private funding initiatives, the MLSC supports innovation, research &
development, commercialization, and manufacturing activities in the fields of biopharma, medical
device, diagnostics, and digital health. Since its creation in 2007, the MLSC has strategically
deployed over $700 million in Massachusetts, through a combination of grants, loans, capital
infrastructure investments, tax incentives, and workforce programs. These investments have
created thousands of jobs, and propelled the development of new therapies, devices, and
scientific advancements that are improving patient health and well-being in Massachusetts and
Ipsen Forward-Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or 4 / 4 revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2016 Registration Document available on its website (www.ipsen.com).